Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies.
Kahalalide F (1) shows remarkable antitumor activity against different carcinomas and has recently completed phase I clinical trials and is being evaluated in phase II clinical studies. The antifungal activity of this molecule has not been thoroughly investigated. In this report, we focused on acetylation and oxidation of the secondary alcohol of threonine, as well as reductive alkylation of the primary amine of ornithine, and each product was evaluated for improvements in antifungal activity. 1 and analogues do not exhibit antimalarial, antileishmania, or antibacterial activity; however, the antifungal activity against different strains of fungi was particularly significant. This series of compounds was highly active against Fusarium spp., which represents an opportunistic infection in humans and plants. The in vitro cytotoxicity for the new analogues of 1 was evaluated in the NCI 60 cell panel. Analogue 5 exhibited enhanced potency in several human cancer cell lines relative to 1.
Shilabin
Abbas Gholipour
AG
Department of Pharmacognosy, School of Pharmacy, The University of Mississippi, University, Mississippi 38677, USA.
Kasanah
Noer
N
Wedge
David E
DE
Hamann
Mark T
MT
D000935:Antifungal Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000977:Antiparasitic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D047630:Depsipeptides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D005670:Fusarium / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008247:Lysosomes / Q000187:drug effects*; D008828:Microbiological Techniques; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009894:Opportunistic Infections / Q000382:microbiology; D021261:Parasitic Sensitivity Tests; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
C523905:4-fluorobenzylaminokahalalide F; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000977:Antiparasitic Agents; D047630:Depsipeptides; C097897:kahalalide F; D020893:Receptor, ErbB-3
Curr Opin Mol Ther. 2004 Dec;6(6):657-65
15663330
Expert Opin Investig Drugs. 2000 Feb;9(2):273-99
11060677
Expert Opin Emerg Drugs. 2002 May;7(1):3-32
15989533
J Nat Prod. 2006 Nov;69(11):1547-53
17125219
J Am Chem Soc. 2005 Jul 6;127(26):9320-1
15984830
J Mass Spectrom. 2007 Jan;42(1):70-80
17149796
J Transl Med. 2006 Jan 09;4:3
16401350
J Org Chem. 1996 Sep 20;61(19):6594-6600
11667527
J Agric Food Chem. 2003 Apr 9;51(8):2246-52
12670165
Mol Cancer Ther. 2003 Sep;2(9):863-72
14555705
J Nat Prod. 2000 Jan;63(1):152-4
10650101
Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23
10348745
J Am Chem Soc. 2001 Nov 21;123(46):11398-401
11707116
Clin Cancer Res. 2005 Mar 1;11(5):1854-62
15756010
J Nat Prod. 2003 Nov;66(11):1466-70
14640520
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
12853564
Mol Pharmacol. 2005 Aug;68(2):502-10
15908515
J Org Chem. 2006 Sep 15;71(19):7196-204
16958512
Antimicrob Agents Chemother. 1997 May;41(5):1004-9
9145860
J Org Chem. 1996 Sep 20;61(19):6720-6722
11667547
Cancer Lett. 1996 Jan 19;99(1):43-50
8564928